Total Payments
$251,222
2024 Payments
$63,464
Companies
50
Transactions
1,423
Medicare Patients
4,675
Medicare Billing
$569,748
Payment Breakdown by Category
Other$210,290 (83.7%)
Food & Beverage$31,219 (12.4%)
Consulting$5,327 (2.1%)
Travel$3,748 (1.5%)
Education$638.70 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $210,290 | 97 | 83.7% |
| Food and Beverage | $31,219 | 1,254 | 12.4% |
| Consulting Fee | $5,327 | 6 | 2.1% |
| Travel and Lodging | $3,748 | 50 | 1.5% |
| Education | $638.70 | 16 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $137,308 | 343 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $92,121 | 340 | $0 (2024) |
| Amgen Inc. | $4,279 | 23 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,532 | 109 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $1,613 | 57 | $0 (2024) |
| United Therapeutics Corporation | $1,452 | 40 | $0 (2024) |
| Mylan Specialty L.P. | $1,188 | 29 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $1,148 | 48 | $0 (2024) |
| GENZYME CORPORATION | $983.51 | 49 | $0 (2024) |
| Genentech USA, Inc. | $804.10 | 49 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $63,464 | 227 | AstraZeneca Pharmaceuticals LP ($36,342) |
| 2023 | $68,326 | 210 | GlaxoSmithKline, LLC. ($53,881) |
| 2022 | $45,075 | 194 | GlaxoSmithKline, LLC. ($26,338) |
| 2021 | $35,190 | 144 | GlaxoSmithKline, LLC. ($20,528) |
| 2020 | $16,675 | 140 | GlaxoSmithKline, LLC. ($10,311) |
| 2019 | $3,787 | 181 | AstraZeneca Pharmaceuticals LP ($1,177) |
| 2018 | $9,950 | 159 | AstraZeneca Pharmaceuticals LP ($8,016) |
| 2017 | $8,754 | 168 | AstraZeneca Pharmaceuticals LP ($5,104) |
All Payment Transactions
1,423 individual payment records from CMS Open Payments — Page 1 of 57
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $32.89 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $32.42 | General |
| Category: Respiratory | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: RESPIRATORY | ||||||
| 12/13/2024 | Philips North America LLC | (AK6) Vest Therapy (Device) | Food and Beverage | Cash or cash equivalent | $16.11 | General |
| Category: Medical Device | ||||||
| 12/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $12.45 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $20.41 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $120.55 | General |
| Category: RESPIRATORY | ||||||
| 12/10/2024 | WATERMARK MEDICAL, INC. | ARES 620 UNICORDER (Device) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: VENTILATORY EFFORT RECORDER | ||||||
| 12/09/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 12/06/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: Respiratory | ||||||
| 12/03/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: NEUROLOGY | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $123.24 | General |
| Category: Respiratory | ||||||
| 12/02/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $37.59 | General |
| Category: NEUROLOGY | ||||||
| 12/02/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $10.80 | General |
| Category: IMMUNOLOGY | ||||||
| 12/01/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: Respiratory | ||||||
| 11/27/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $31.82 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: Respiratory | ||||||
| 11/18/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $134.76 | General |
| Category: HFCWO | ||||||
| 11/15/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $39.94 | General |
| Category: NEUROLOGY | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $119.70 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $120.83 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 762 | 1,172 | $257,745 | $97,081 |
| 2022 | 10 | 918 | 1,501 | $306,885 | $105,666 |
| 2021 | 11 | 1,463 | 2,645 | $576,659 | $179,718 |
| 2020 | 11 | 1,532 | 2,806 | $614,655 | $187,282 |
Total Patients
4,675
Total Services
8,124
Medicare Billing
$569,748
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 298 | 485 | $133,375 | $46,152 | 34.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 146 | 326 | $42,380 | $20,564 | 48.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 64 | 64 | $22,400 | $7,497 | 33.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 39 | 61 | $11,590 | $5,953 | 51.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 73 | 93 | $17,670 | $5,856 | 33.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 52 | 52 | $12,740 | $5,466 | 42.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 24 | $8,640 | $3,413 | 39.5% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 15 | 15 | $2,625 | $943.73 | 36.0% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 19 | 19 | $2,280 | $620.08 | 27.2% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 16 | 16 | $1,920 | $388.35 | 20.2% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 17 | 17 | $2,125 | $227.08 | 10.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 281 | 645 | $102,150 | $37,680 | 36.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 220 | 369 | $105,800 | $36,739 | 34.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 124 | 163 | $31,810 | $10,227 | 32.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 72 | 101 | $24,890 | $8,426 | 33.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 54 | 54 | $22,000 | $6,152 | 28.0% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 44 | 44 | $4,890 | $2,168 | 44.3% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 41 | 41 | $4,560 | $1,885 | 41.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 44 | 44 | $7,710 | $1,447 | 18.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 19 | 19 | $2,325 | $593.37 | 25.5% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2022 | 19 | 21 | $750.00 | $348.18 | 46.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 378 | 1,380 | $271,578 | $83,810 | 30.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 191 | 259 | $75,330 | $28,274 | 37.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 264 | 350 | $68,992 | $24,032 | 34.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 167 | 186 | $83,700 | $21,282 | 25.4% |
About Dr. Steven Geller, DO
Dr. Steven Geller, DO is a Pulmonary Disease healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1194836387.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Geller, DO has received a total of $251,222 in payments from pharmaceutical and medical device companies, with $63,464 received in 2024. These payments were reported across 1,423 transactions from 50 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($210,290).
As a Medicare-enrolled provider, Geller has provided services to 4,675 Medicare beneficiaries, totaling 8,124 services with total Medicare billing of $569,748. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Philadelphia, PA
- Active Since 08/31/2006
- Last Updated 01/29/2014
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1194836387
Products in Payments
- TRELEGY ELLIPTA (Drug) $45,347
- BREZTRI (Drug) $36,657
- TEZSPIRE (Biological) $34,301
- AREXVY (Drug) $19,790
- BEVESPI AEROSPHERE (Drug) $10,113
- SYMBICORT (Drug) $4,384
- BREZTRI AEROSPHERE (Drug) $3,837
- DUPIXENT (Biological) $2,522
- FASENRA (Biological) $2,178
- Yupelri (Drug) $1,025
- NUCALA (Biological) $1,012
- STIOLTO RESPIMAT (Drug) $864.21
- Xolair (Biological) $649.87
- TYVASO (Drug) $628.88
- GLASSIA (Biological) $626.93
- XYWAV (Drug) $560.62
- Arikayce (Drug) $544.48
- ANORO (Drug) $537.34
- OFEV (Drug) $475.51
- OPSUMIT (Drug) $472.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Philadelphia
Gerard Criner, Md, MD
Pulmonary Disease — Payments: $945,674
Pulmonary Disease $945,674
Jeffrey Edelson, M.d, M.D
Pulmonary Disease — Payments: $437,125
Pulmonary Disease $437,125
Parth Rali, Md, MD
Pulmonary Disease — Payments: $232,570
Pulmonary Disease $232,570
Boyd Hehn, Md, MD
Pulmonary Disease — Payments: $139,719
Pulmonary Disease $139,719
Edward Schulman, Md, MD
Pulmonary Disease — Payments: $132,370
Pulmonary Disease $132,370
Gary Aaronson, Do, DO
Pulmonary Disease — Payments: $127,540
Pulmonary Disease $127,540